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Introduction:  
 
Human proto-oncogene tyrosine-protein kinase YES (YES) is a non receptor kinase belongs to Src family. This gene lies in close proximity to thymidylate synthase gene on chromosome 18. In 
hepatocellular carcinoma and colorectal carcinoma elevated human YES activity was observed. Inhibitors of human YES reported till date are in clinical trials and associated with several side ef-
fects. The present study was mainly aimed in homology modeling of YES and discovery of novel lead molecules that inhibit YES kinase more efficiently with less side effects. Virtual screening 
and docking techniques using Schrodinger software suite (Maestro 9.0) were applied to identify novel lead molecule of YES kinase. Ligand based virtual screening using modeled structure of YES 
protein resulted in identification of thirteen lead molecules. 
METHOD: 
RESULTS:  
Docking complex of  human YES kinase and Lead ‘1’ had 
deciphered that the amino acid residues of YES kinase 
such as Leu-283, Gly-284, Val-291, Ala-303, Ile-304, Lys-
305, Met-324, Val-333, Leu-335, Ile-346, Thr-348, Gly-
354, Ser-355, Leu-361, Ala-400, Leu-403, Ala-413, Asp-
414, Phe-415, Gly-416 and Leu-417 are involved in mo-
lecular interaction.  
Conclusion: Compared to five published inhibitors Lead ‘1’ molecule was having least XP Gscore of -12.07 Kcal/
mol  and molecular weight 424.51 Daltons. Therefore Lead ’1’  can be raised into potential inhibitors after binding 
assays and passing several phases of clinical trials.  
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Figure 1. Role of YES in adherens junction formation pathway  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
10
.4
90
2.
1 
: P
os
te
d 
15
 S
ep
 2
01
0
